An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer [EXTENSION OF 700012740]
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Amgen
- 12 Mar 2015 Last checked against ClinicalTrials.gov record.
- 24 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01824342).